ZBIO Quote, Financials, Valuation and Earnings

Aquestive Therapeutics, Inc. has a net margin of -335.73% compared to Zenas BioPharma, Inc.'s net margin of -120.61%. Zenas BioPharma, Inc.'s return on equity of -68.2% beat Aquestive Therapeutics, Inc.'s return on equity of --.

Zenas BioPharma, Inc. has a consensus price target of $45.00, signalling upside risk potential of 22.72%. On the other hand Aquestive Therapeutics, Inc. has an analysts' consensus of $10.30 which suggests that it could grow by 67.48%. Given that Aquestive Therapeutics, Inc. has higher upside potential than Zenas BioPharma, Inc., analysts believe Aquestive Therapeutics, Inc. is more attractive than Zenas BioPharma, Inc..

Zenas BioPharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aquestive Therapeutics, Inc. has a beta of 1.590, suggesting its more volatile than the S&P 500 by 59.015%.

Zenas BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aquestive Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zenas BioPharma, Inc. pays -- of its earnings as a dividend. Aquestive Therapeutics, Inc. pays out -- of its earnings as a dividend.

Zenas BioPharma, Inc. quarterly revenues are --, which are smaller than Aquestive Therapeutics, Inc. quarterly revenues of $12.8M. Zenas BioPharma, Inc.'s net income of -$51.5M is lower than Aquestive Therapeutics, Inc.'s net income of -$15.4M. Notably, Zenas BioPharma, Inc.'s price-to-earnings ratio is -- while Aquestive Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zenas BioPharma, Inc. is 102.44x versus 14.05x for Aquestive Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bristol Myers Squibb Co. has a net margin of -335.73% compared to Zenas BioPharma, Inc.'s net margin of 17.96%. Zenas BioPharma, Inc.'s return on equity of -68.2% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.

Zenas BioPharma, Inc. has a consensus price target of $45.00, signalling upside risk potential of 22.72%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $53.05 which suggests that it could grow by 4.09%. Given that Zenas BioPharma, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Zenas BioPharma, Inc. is more attractive than Bristol Myers Squibb Co..

Zenas BioPharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.

Zenas BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.87% to investors and pays a quarterly dividend of $0.62 per share. Zenas BioPharma, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zenas BioPharma, Inc. quarterly revenues are --, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Zenas BioPharma, Inc.'s net income of -$51.5M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Zenas BioPharma, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 17.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zenas BioPharma, Inc. is 102.44x versus 2.16x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -335.73% compared to Zenas BioPharma, Inc.'s net margin of 33.68%. Zenas BioPharma, Inc.'s return on equity of -68.2% beat Merck & Co., Inc.'s return on equity of 39.63%.

Zenas BioPharma, Inc. has a consensus price target of $45.00, signalling upside risk potential of 22.72%. On the other hand Merck & Co., Inc. has an analysts' consensus of $105.35 which suggests that it could grow by 3.01%. Given that Zenas BioPharma, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Zenas BioPharma, Inc. is more attractive than Merck & Co., Inc..

Zenas BioPharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Zenas BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.17% to investors and pays a quarterly dividend of $0.81 per share. Zenas BioPharma, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zenas BioPharma, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Zenas BioPharma, Inc.'s net income of -$51.5M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Zenas BioPharma, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zenas BioPharma, Inc. is 102.44x versus 4.03x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Royalty Pharma Plc has a net margin of -335.73% compared to Zenas BioPharma, Inc.'s net margin of 72.91%. Zenas BioPharma, Inc.'s return on equity of -68.2% beat Royalty Pharma Plc's return on equity of 13.15%.

Zenas BioPharma, Inc. has a consensus price target of $45.00, signalling upside risk potential of 22.72%. On the other hand Royalty Pharma Plc has an analysts' consensus of $45.54 which suggests that it could grow by 16.12%. Given that Zenas BioPharma, Inc. has higher upside potential than Royalty Pharma Plc, analysts believe Zenas BioPharma, Inc. is more attractive than Royalty Pharma Plc.

Zenas BioPharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Royalty Pharma Plc has a beta of 0.466, suggesting its less volatile than the S&P 500 by 53.41%.

Zenas BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Royalty Pharma Plc offers a yield of 2.22% to investors and pays a quarterly dividend of $0.22 per share. Zenas BioPharma, Inc. pays -- of its earnings as a dividend. Royalty Pharma Plc pays out 43.94% of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zenas BioPharma, Inc. quarterly revenues are --, which are smaller than Royalty Pharma Plc quarterly revenues of $609.3M. Zenas BioPharma, Inc.'s net income of -$51.5M is lower than Royalty Pharma Plc's net income of $444.2M. Notably, Zenas BioPharma, Inc.'s price-to-earnings ratio is -- while Royalty Pharma Plc's PE ratio is 22.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zenas BioPharma, Inc. is 102.44x versus 9.64x for Royalty Pharma Plc. Usually stocks with elevated PS ratios are considered overvalued.